228 related articles for article (PubMed ID: 37137901)
1. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss.
Rüland L; Andreatta F; Massalini S; Chuva de Sousa Lopes S; Clevers H; Hendriks D; Artegiani B
Nat Commun; 2023 May; 14(1):2377. PubMed ID: 37137901
[TBL] [Abstract][Full Text] [Related]
2. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
4. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.
Dinh TA; Jewell ML; Kanke M; Francisco A; Sritharan R; Turnham RE; Lee S; Kastenhuber ER; Wauthier E; Guy CD; Yeung RS; Lowe SW; Reid LM; Scott JD; Diehl AM; Sethupathy P
Cell Mol Gastroenterol Hepatol; 2019; 7(4):803-817. PubMed ID: 30763770
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.
Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
[TBL] [Abstract][Full Text] [Related]
7. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
Ma RK; Tsai PY; Farghli AR; Shumway A; Kanke M; Gordan JD; Gujral TS; Vakili K; Nukaya M; Noetzli L; Ronnekleiv-Kelly S; Broom W; Barrow J; Sethupathy P
PLoS Genet; 2024 Mar; 20(3):e1011216. PubMed ID: 38512964
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma.
Jewell ML; Gibson JR; Guy CD; Hyun J; Du K; Oh SH; Premont RT; Hsu DS; Ribar T; Gregory SG; Diehl AME
Am J Pathol; 2020 Jan; 190(1):93-107. PubMed ID: 31669305
[TBL] [Abstract][Full Text] [Related]
9. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
[TBL] [Abstract][Full Text] [Related]
10. Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
Francisco AB; Kanke M; Massa AP; Dinh TA; Sritharan R; Vakili K; Bardeesy N; Sethupathy P
JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35482409
[TBL] [Abstract][Full Text] [Related]
11. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
[TBL] [Abstract][Full Text] [Related]
13. Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids.
Artegiani B; van Voorthuijsen L; Lindeboom RGH; Seinstra D; Heo I; Tapia P; López-Iglesias C; Postrach D; Dayton T; Oka R; Hu H; van Boxtel R; van Es JH; Offerhaus J; Peters PJ; van Rheenen J; Vermeulen M; Clevers H
Cell Stem Cell; 2019 Jun; 24(6):927-943.e6. PubMed ID: 31130514
[TBL] [Abstract][Full Text] [Related]
14. DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient.
Balbeur S; Dumortier A; Mergen J; Libbrecht L; Torbenson M; Boulanger C; de Ville de Goyet M; Van Damme A; Brichard B
Pediatr Blood Cancer; 2020 Feb; 67(2):e28060. PubMed ID: 31736218
[TBL] [Abstract][Full Text] [Related]
15.
Kastenhuber ER; Lalazar G; Houlihan SL; Tschaharganeh DF; Baslan T; Chen CC; Requena D; Tian S; Bosbach B; Wilkinson JE; Simon SM; Lowe SW
Proc Natl Acad Sci U S A; 2017 Dec; 114(50):13076-13084. PubMed ID: 29162699
[TBL] [Abstract][Full Text] [Related]
16. DnaJ-PKAc fusion induces liver inflammation in a zebrafish model of fibrolamellar carcinoma.
de Oliveira S; Houseright RA; Korte BG; Huttenlocher A
Dis Model Mech; 2020 Apr; 13(4):. PubMed ID: 32102783
[TBL] [Abstract][Full Text] [Related]
17. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.
Toyota A; Goto M; Miyamoto M; Nagashima Y; Iwasaki S; Komatsu T; Momose T; Yoshida K; Tsukada T; Matsufuji T; Ohno A; Suzuki M; Ubukata O; Kaneta Y
Biochem Biophys Res Commun; 2022 Sep; 621():157-161. PubMed ID: 35839742
[TBL] [Abstract][Full Text] [Related]
18. DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
Kirk AM; Crawford JC; Chou CH; Guy C; Pandey K; Kozlik T; Shah RK; Chung S; Nguyen P; Zhang X; Wang J; Bell M; Mettelman RC; Allen EK; Pogorelyy MV; Kim H; Minervina AA; Awad W; Bajracharya R; White T; Long D; Gordon B; Morrison M; Glazer ES; Murphy AJ; Jiang Y; Fitzpatrick EA; Yarchoan M; Sethupathy P; Croft NP; Purcell AW; Federico SM; Stewart E; Gottschalk S; Zamora AE; DeRenzo C; Strome SE; Thomas PG
Cell Rep Med; 2024 Mar; 5(3):101469. PubMed ID: 38508137
[TBL] [Abstract][Full Text] [Related]
19. DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling.
Kim SS; Kycia I; Karski M; Ma RK; Bordt EA; Kwan J; Karki A; Winter E; Aktas RG; Wu Y; Emili A; Bauer DE; Sethupathy P; Vakili K
PLoS One; 2022; 17(2):e0263829. PubMed ID: 35167623
[TBL] [Abstract][Full Text] [Related]
20. A framework for fibrolamellar carcinoma research and clinical trials.
Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
